Increased bioavailability when given w/ a high-fat meal.
May induce positive direct Comb's test. False-positive urine glucose results may occur when using Clinitest®, Benedict's or Fehling's soln. False negative result may occur in ferricyanide test.
Description: Cefditoren binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Pharmacokinetics: Absorption: Absorbed from the GI tract. Increased bioavailability when given w/ a high-fat meal. Bioavailability: Approx 14% (fasting state). Time to peak plasma concentration: 1.5-3 hr. Distribution: Volume of distribution: 9.3±1.6 L. Plasma protein binding: 88% (primarily to albumin). Metabolism: Not appreciably metabolised. Hydrolysed by esterases to cefditoren (active component) and pivalate. Excretion: Mainly via urine by glomerular filtration and tubular secretion. Plasma half-life: Approx 1.6 hr.
Anon. Cefditoren. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/11/2014.Buckingham R (ed). Cefditoren Pivoxil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/11/2014.McEvoy GK, Snow EK, Miller J et al (eds). Cefditoren Pivoxil. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 05/11/2014.Spectracef Tablet, Film Coated (Vansen Pharma Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/11/2014.